According to Qnovia, which recently changed its name from Respira Technologies, the company has closed a $17 million Series A financing round led by Blue Ledge Capital, with the funds intended to support development of the company's RespiRx inhaled nicotine replacement therapy (NRT). The company said that it intends to submit an IND for the NRT product and anticipates … [Read more...] about Qnovia raises $17 million for development of inhaled nicotine replacement therapy
Business
RS BioTherapeutics raises $3 million for development of RSBT-001 inhaled cannabidiolic acid
RS BioTherapeutics, which recently announced positive results from a proof of concept study of its RSBT-001 semi-synthetic cannabidiolic acid (CBDa) in a mouse model, said that the company has raised $3 million in a Seed II funding round. The company says that it is partnered with Synthonics and Marshall University on development of a nebulized formulation of RSBT-001 … [Read more...] about RS BioTherapeutics raises $3 million for development of RSBT-001 inhaled cannabidiolic acid
Recipharm joins IPAC-RS
CDMO and device maker Recipharm has joined the International Pharmaceutical Aerosol Consortium on Regulation and Science (IPAC-RS) as a member, the company announced. Recipharm will be represented on the IPAC-RS Board by Head of Commercial – Advanced Delivery Systems Peter Hirst and Director of Inhalation Sciences and Product Development Lei Mao. According to … [Read more...] about Recipharm joins IPAC-RS
Startup Moat Biotechnology announces funding round, positive interim Phase 1 results for its intranasal COVID-19 vaccine
Startup Moat Biotechnology announced the initiation of a funding round led by Cortado Ventures that aims to raise up to $20 million for continued development of the company's intranasal vaccine against COVID-19. According to the announcement, Tetherex Pharmaceuticals has spun out MoatBio in order to develop single-cycle adenovirus vaccines based on SC-AdVax … [Read more...] about Startup Moat Biotechnology announces funding round, positive interim Phase 1 results for its intranasal COVID-19 vaccine
Akorn settles False Claims Act case involving continued sales of azelastine nasal spray as prescription-only after OTC conversion
The US Department of Justice has announced that Akorn will pay $7.9 million to settle a case related to submission of false claims to Medicare Part D after the company continued to sell three products, including azelastine nasal spray, as prescription drugs after conversion to over-the-counter. The allegations were initially made in a suit brought by a whistleblower … [Read more...] about Akorn settles False Claims Act case involving continued sales of azelastine nasal spray as prescription-only after OTC conversion
RIGImmune to develop intranasal stem-loop RNA therapeutics
Yale University spinout RIGImmune, which has been developing stemloop RNA (SLR) therapeutics, announced that it has acquired biotech Subintro, which has been working on antivirals for RNA virus-caused respiratory infections. The company will now develop intranasal therapeutics "that both activate the natural immune activation and demonstrate antiviral activity," … [Read more...] about RIGImmune to develop intranasal stem-loop RNA therapeutics
ALS Association to fund preclinical study of intranasal foralumab
According to Tiziana Life Sciences, The ALS Association will award a Lawrence & Isabel Barnett Drug Development Program Grant to the Ann Romney Center for Neurologic Diseases at the Brigham and Women’s Hospital (BWH) for a preclinical study of Tiziana's intranasal foralumab anti-CD3 monoclonal antibody. The company said that researchers at BWH will evaluate the … [Read more...] about ALS Association to fund preclinical study of intranasal foralumab
Respira Technologies changes its name to Qnovia
Nebulizer developer Respira Technologies, which recently announced the appointment of Brian Quigley as CEO, has changed its name to "Qnovia," the company said. No reason for the name change was announced, but the previous name was similar to that of Respira Therapeutics, which is developing a vardenafil DPI for the treatment of pulmonary arterial hypertension … [Read more...] about Respira Technologies changes its name to Qnovia
Iliad Biotechnology raises $42.8 million for Phase 2b study of BPZE1 intranasal pertussis vaccine
Illiad Biotechnologies has closed a $42.8 million financing round, the company said, with the funds intended to support a Phase 2b challenge study of the company's BPZE1 intranasal pertussis vaccine as well as other development and manufacturing activities. The company said that the new funding brings the total for development of BPZE1 to more than $100 … [Read more...] about Iliad Biotechnology raises $42.8 million for Phase 2b study of BPZE1 intranasal pertussis vaccine
Court rules that Liquidia’s Yutrepia treprostinil DPI would infringe United Therapeutics patents covering Tyvaso
The United States District Court for the District of Delaware has ruled that Liquidia's Yutrepia treprostinil DPI would infringe claims contained in US patents 9,593,066 and 10,716,793, which cover United Therapeutics' Tyvaso inhaled treprostinil; however, the judge found that the claims in the '066 patent that would be infringed are invalid and the sole valid claim … [Read more...] about Court rules that Liquidia’s Yutrepia treprostinil DPI would infringe United Therapeutics patents covering Tyvaso